26 results
8-K
EX-99.1
BEAM
Beam Therapeutics Inc
7 May 24
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
7:09am
.
Research & Development (R&D) Expenses: R&D expenses were $84.8 million for the first quarter of 2024, compared to $99.6 million for the first
8-K
EX-99.1
BEAM
Beam Therapeutics Inc
27 Feb 24
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
6:43am
billion as of December 31, 2022.
Research & Development (R&D) Expenses: R&D expenses were $140.1 million for the fourth quarter of 2023 and $437.4
8-K
EX-99.1
BEAM
Beam Therapeutics Inc
8 Nov 23
Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results
7:00am
, 2023, as compared to $1.1 billion as of December 31, 2022.
Research & Development (R&D) Expenses: R&D expenses were $100.0 million for the third quarter
8-K
EX-99.1
BEAM
Beam Therapeutics Inc
8 Aug 23
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results
7:11am
30, 2023, as compared to $1.1 billion as of December 31, 2022.
Research & Development (R&D) Expenses: R&D expenses were $97.6 million for the second
8-K
EX-99.1
BEAM
Beam Therapeutics Inc
10 May 23
Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results
7:00am
as of December 31, 2022.
Research & Development (R&D) Expenses: R&D expenses were $99.6 million for the first quarter of 2023, compared to $65.4
8-K
EX-99.1
uh8vyt22olepq6s c4l3
7 Nov 22
Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results
7:00am
8-K
EX-99.1
vn5gjzi5c8p
9 Aug 22
Beam Therapeutics Announces Pipeline and Business Highlights and Reports Second Quarter 2022 Financial Results
7:00am
8-K
EX-99.1
ilisg1 smyy2
9 May 22
Beam Therapeutics Announces Pipeline and Business Highlights and Reports First Quarter 2022 Financial Results
7:01am
8-K
EX-99.1
063j 8l3ktf2as4uat2
28 Feb 22
Beam Therapeutics Reports Pipeline and Business Highlights, Planned 2022 Milestones and Fourth Quarter and Full Year 2021 Financial Results
7:00am
8-K
EX-99.1
cw0ajlh1
8 Nov 21
Beam Therapeutics Provides Business and Pipeline Updates and Reports Third Quarter 2021 Financial Results
6:19am
8-K
EX-99.1
ehs hyqtg
10 Aug 21
Beam Therapeutics Provides Business and Pipeline Updates and Reports Second Quarter 2021 Financial Results
6:46am
8-K
EX-99.1
8bel xi9o
11 May 21
Beam Therapeutics Presents LNP Formulation Data at ASGCT and Reports First Quarter 2021 Financial Results
7:48am
8-K
EX-99.1
klupdn
15 Mar 21
Beam Therapeutics Announces Business and Pipeline Progress and Reports Fourth Quarter and Full Year 2020 Financial Results
6:45am
8-K
EX-99.1
gzj72dp6no0pfxk
10 Nov 20
Beam Therapeutics Announces Business and Pipeline Progress and Reports Third Quarter 2020 Financial Results
6:41am
8-K
EX-99.1
8votakl bpvwt1le05g
12 Aug 20
Beam Therapeutics Announces First Development Candidates for Sickle Cell Disease and Reports Second Quarter 2020 Results
7:30am
8-K
EX-99.1
zojv1
12 May 20
Beam Therapeutics Reports Additional Data at ASGCT Annual Meeting and First Quarter 2020 Financial Results
10:52am
10-K
wsfx5nkr9i bajk
30 Mar 20
Annual report
5:26pm
8-K
EX-99.1
g8vvfctr9 s8s
30 Mar 20
Beam Therapeutics Reports Business Updates and Full Year 2019 Financial Results
6:45am
424B4
f81jptw9j9w4usvxj
7 Feb 20
Prospectus supplement with pricing info
12:00am